Madeleine Stone is a Vice President and Equity Research Analyst at William Blair, where she specializes in covering dental and medical device companies such as Dentsply Sirona, Align Technology, and Straumann Group. She joined William Blair in 2019 and has developed a reputation for detailed sector research and insightful investment recommendations, maintaining above-average success rates and positive average returns on platforms tracking analyst performance. Prior to her current role, she held positions in investment banking and research at Citigroup and completed her education at the University of Notre Dame with a focus on finance. Madeleine holds FINRA Series 7, 63, and 86/87 licenses, underscoring her qualifications and commitment to investment research excellence.
Madeleine Stone, on behalf of Matt Phipps from William Blair, asked how much additional follow-up data from the Phase II trial would be required for future discussions with the FDA.
CEO Garo Armen responded that approximately six more months of follow-up data would be needed compared to what was included in the data package previously submitted to the FDA.